Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Calidi BiotherapeuticsCLDI +2.85%12 3-Year EBITDA Growth Rate is 63.00% as of Mar. 2026, which is 1300% above its 10-year median of 4.50. GuruFocus rates CLDI with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,137 Biotechnology companies, Calidi Biotherapeutics ranks better than 91.03% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 63.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 21.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Calidi Biotherapeutics was 63.00% per year. The lowest was -95.70% per year. And the median was 4.50% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Calidi Biotherapeutics 3-Year EBITDA Growth Rate Related Terms
CLDI vs DCOY, CDT, ACUT: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Calidi Biotherapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Calidi Biotherapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Calidi Biotherapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Calidi Biotherapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 63.00% mean?
Calidi Biotherapeutics (CLDI) has a 3-Year EBITDA Growth Rate of 63.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Calidi Biotherapeutics and its competitors. This is 1300% above median its historical median of 4.50. According to the industry distribution chart, Calidi Biotherapeutics ranks #102 out of 1137 companies in the Biotechnology industry, placing it in the top 9%.
Is Calidi Biotherapeutics' 3-Year EBITDA Growth Rate too high?
Calidi Biotherapeutics' current 3-Year EBITDA Growth Rate of 63.00% is 1300% above median its 10-year median of 4.50. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Calidi Biotherapeutics' value of 63.00% is 322.8% above this industry median. Based on the distribution chart, Calidi Biotherapeutics ranks #102 out of 1137 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Calidi Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Calidi Biotherapeutics' 3-Year EBITDA Growth Rate compare to DCOY and CDT?
According to the Biotechnology industry distribution chart, Calidi Biotherapeutics ranks #102 out of 1137 companies for 3-Year EBITDA Growth Rate. This places Calidi Biotherapeutics in the top 9% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.90. Calidi Biotherapeutics' value of 63.00% is 322.8% above this benchmark. While the company's 10-year median is 4.50 vs. the industry median of 14.90, Calidi Biotherapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,137 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Calidi Biotherapeutics's current 3-Year EBITDA Growth Rate of 63.00% is 322.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Calidi Biotherapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Calidi Biotherapeutics's current 3-Year EBITDA Growth Rate is 63.00%, which is 1300% above median its own 10-year median of 4.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Calidi Biotherapeutics stock overvalued right now?
Calidi Biotherapeutics (CLDI) has a current 3-Year EBITDA Growth Rate of 63.00%. The current 3-Year EBITDA Growth Rate is 63.00%, which is 1300% above median its 10-year median of 4.50 and 322.8% above the Biotechnology industry median of 14.90. Calidi Biotherapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Calidi Biotherapeutics (CLDI), the current 3-Year EBITDA Growth Rate is 63.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
12GF Score
Get the complete analysis for CLDI
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLDI has been successfully added to your 
